US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

59.97

-1.7400-2.82%

Pre-market: 58.70-1.2700-2.12%06:43 EST

Volume:1.01M

Turnover:61.40M

Market Cap:4.15B

PE:-19.23

High:62.49

Open:61.50

Low:59.92

Close:61.71

52wk High:94.90

52wk Low:13.22

Shares:69.14M

Float Shares:49.03M

Volume Ratio:0.44

T/O Rate:2.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1192

EPS(LYR):-2.3276

ROE:-25.28%

ROA:-17.53%

PB:5.38

PE(LYR):-25.76

Loading ...

Overview Company News Filings

Structure details positive trial data for a weight-loss pill, and the stock rockets

Structure Therapeutics Shares Reverse Course, Last Down 15% Premarket

THOMSON REUTERS

Structure's experimental pill shows 11% weight loss in study, shares up

Structure Therapeutics Shares Jump 30% Premarket After Data for Its Weight-Loss Drug

THOMSON REUTERS

Structure Therapeutics Reports Positive Topline Data From Access Program for Its Once-Daily Oral Small Molecule Glp-1 Receptor Agonist, Aleniglipron

THOMSON REUTERS

Structure Therapeutics Inc - Aleniglipron to Advance to Phase 3 Clinical Development

THOMSON REUTERS

Structure Therapeutics Inc - Aleniglipron Achieves 11.3% Weight Loss With 120 Mg Dose

THOMSON REUTERS

Structure Therapeutics Inc - No Treatment Discontinuations at Lower 2.5 Mg Dose in Access Program

THOMSON REUTERS

BUZZ-Structure Therapeutics down ahead of weight-loss drug data

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Jefferies Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Structure Therapeutics Inc. Q3 Net Income USD -65.712 Million

Stock Track | Structure Therapeutics (GPCR) Soars 5% Pre-Market on Promising Obesity Drug Results

Press Release: Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

The Bull Case For Structure Therapeutics (GPCR) Could Change Following Key Oral Obesity Drug Data Readouts

Simply Wall St.

Stifel Nicolaus Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Structure Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Structure Therapeutics Inc. unveils strategy to expand access to oral obesity treatments

Structure Therapeutics Q3 loss widens to $65.7 mln

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GPCR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GPCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":59.97,"timestamp":1766005200000,"preClose":61.71,"halted":0,"volume":1007173,"hourTrading":{"tag":"盘前","latestPrice":58.7,"preClose":59.97,"latestTime":"06:43 EST","volume":556,"amount":32463.97264,"timestamp":1766058212822},"delay":0,"floatShares":49026700,"shares":69139200,"eps":-3.119226,"marketStatus":"Pre-Mkt","change":-1.74,"latestTime":"12-18 06:48:45 EST","open":61.5,"high":62.49,"low":59.92,"amount":61395778.485479,"amplitude":0.041646,"askPrice":59,"askSize":192,"bidPrice":58,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-3.119226,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766068200000},"marketStatusCode":1,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":59.97,"preHourTrading":{"tag":"盘前","latestPrice":58.7,"preClose":59.97,"latestTime":"06:43 EST","volume":556,"amount":32463.97264,"timestamp":1766058212822},"postHourTrading":{"tag":"盘后","latestPrice":59.97,"preClose":59.97,"latestTime":"19:51 EST","volume":7834,"amount":469478.3317,"timestamp":1766019082005},"volumeRatio":0.4364583901764155,"impliedVol":0.7351,"impliedVolPercentile":0.3454},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","floatShares":49026700,"roa":"-17.53%","roe":"-25.28%","lyrEps":-2.327592,"volumeRatio":0.4364583901764155,"shares":69139200,"dividePrice":0,"high":62.49,"amplitude":0.041646,"preClose":61.71,"low":59.92,"week52Low":13.22,"pbRate":"5.38","week52High":94.9,"institutionHeld":0,"latestPrice":59.97,"committee":0.219512,"eps":-3.119226,"divideRate":0,"volume":1007173,"delay":0,"ttmEps":-3.119226,"open":61.5,"prevYearClose":27.12,"prevWeekClose":67.06,"prevMonthClose":35.81,"prevQuarterClose":28,"fiveDayClose":68.94,"twentyDayClose":34.5,"sixtyDayClose":24.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GPCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"GPCR","fiscalQuarterEnding":"2025/09","expectedEps":-0.36,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.37},{"market":"US","date":"2025-08-06","symbol":"GPCR","fiscalQuarterEnding":"2025/06","expectedEps":-0.28,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":-0.36},{"market":"US","date":"2025-05-08","symbol":"GPCR","fiscalQuarterEnding":"2025/03","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2025-02-27","symbol":"GPCR","fiscalQuarterEnding":"2024/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2024-11-13","symbol":"GPCR","fiscalQuarterEnding":"2024/09","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GPCR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GPCR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":14,"updateTime":1757307600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GPCR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GPCR","date":"2025-12-16","current":-19.225923,"percent":0.482066,"low":-50.180001,"twenty":-23.640072,"median":-18.097181,"eighty":-9.836213,"high":-5.211405,"avg":-18.682712,"sd":8.807448,"marketCap":3931911072},"quantilePoints":[{"date":"2023-02-03","current":-25.001825,"twenty":-43.272389,"median":-43.272389,"eighty":-32.310051,"marketCap":951294422},{"date":"2023-02-10","current":-22.116999,"twenty":-35.964163,"median":-23.496907,"eighty":-22.21316,"marketCap":841529681},{"date":"2023-02-17","current":-21.285207,"twenty":-24.521021,"median":-22.645883,"eighty":-21.915061,"marketCap":809880847},{"date":"2023-02-24","current":-23.36709,"twenty":-23.715192,"median":-22.645883,"eighty":-21.847749,"marketCap":889094402},{"date":"2023-03-03","current":-25.530709,"twenty":-24.422936,"median":-22.718004,"eighty":-21.972757,"marketCap":971417957},{"date":"2023-03-10","current":-22.636267,"twenty":-24.85566,"median":-22.790125,"eighty":-22.063149,"marketCap":861287334},{"date":"2023-03-17","current":-22.232392,"twenty":-24.422936,"median":-22.70358,"eighty":-22.09392,"marketCap":845920270},{"date":"2023-03-24","current":-21.876596,"twenty":-23.762311,"median":-22.568955,"eighty":-21.891982,"marketCap":832382619},{"date":"2023-03-31","current":-16.960589,"twenty":-23.565181,"median":-22.314128,"eighty":-21.634271,"marketCap":870434396},{"date":"2023-04-06","current":-17.823234,"twenty":-23.376706,"median":-22.232392,"eighty":-21.285207,"marketCap":914706175},{"date":"2023-04-14","current":-17.473898,"twenty":-23.36709,"median":-22.116999,"eighty":-18.643102,"marketCap":896777933},{"date":"2023-04-21","current":-17.210114,"twenty":-23.194,"median":-22.059302,"eighty":-17.623613,"marketCap":883240282},{"date":"2023-04-28","current":-17.815518,"twenty":-23.078607,"median":-21.876596,"eighty":-17.586227,"marketCap":914310203},{"date":"2023-05-05","current":-17.709107,"twenty":-22.982446,"median":-21.689083,"eighty":-17.623613,"marketCap":908849077},{"date":"2023-05-12","current":-17.00755,"twenty":-22.790125,"median":-21.491953,"eighty":-17.586227,"marketCap":956079400},{"date":"2023-05-19","current":-15.32957,"twenty":-22.780509,"median":-20.818827,"eighty":-17.473898,"marketCap":861751761},{"date":"2023-05-26","current":-19.808636,"twenty":-22.761276,"median":-19.808636,"eighty":-17.466769,"marketCap":1113542462},{"date":"2023-06-02","current":-21.830342,"twenty":-22.668962,"median":-20.674586,"eighty":-17.472472,"marketCap":1227192672},{"date":"2023-06-09","current":-23.110075,"twenty":-22.668962,"median":-21.38858,"eighty":-17.563702,"marketCap":1299132872},{"date":"2023-06-16","current":-21.061141,"twenty":-22.668962,"median":-21.491953,"eighty":-17.586212,"marketCap":1183952020},{"date":"2023-06-23","current":-21.782692,"twenty":-22.640113,"median":-21.568882,"eighty":-17.608538,"marketCap":1224514048},{"date":"2023-06-30","current":-27.561913,"twenty":-22.772816,"median":-21.571672,"eighty":-17.623492,"marketCap":1549392931},{"date":"2023-07-07","current":-24.451072,"twenty":-23.059375,"median":-21.612515,"eighty":-17.625039,"marketCap":1374517018},{"date":"2023-07-14","current":-21.428724,"twenty":-23.103781,"median":-21.707815,"eighty":-17.644282,"marketCap":1204615694},{"date":"2023-07-21","current":-23.069233,"twenty":-23.103781,"median":-21.780436,"eighty":-17.700571,"marketCap":1296836908},{"date":"2023-07-28","current":-23.552536,"twenty":-23.333385,"median":-21.782692,"eighty":-17.727736,"marketCap":1324005814},{"date":"2023-08-04","current":-21.592094,"twenty":-23.51737,"median":-21.782692,"eighty":-17.804907,"marketCap":1213799550},{"date":"2023-08-11","current":-19.978813,"twenty":-23.374783,"median":-21.781564,"eighty":-17.817061,"marketCap":1123108978},{"date":"2023-08-18","current":-16.072919,"twenty":-23.333385,"median":-21.735043,"eighty":-17.644282,"marketCap":1053531639},{"date":"2023-08-25","current":-16.66259,"twenty":-23.197654,"median":-21.646551,"eighty":-17.586168,"marketCap":1092182818},{"date":"2023-09-01","current":-16.458249,"twenty":-23.185384,"median":-21.592094,"eighty":-17.468195,"marketCap":1078788845},{"date":"2023-09-08","current":-16.680105,"twenty":-23.150918,"median":-21.568882,"eighty":-17.319402,"marketCap":1093330873},{"date":"2023-09-15","current":-18.326514,"twenty":-23.110075,"median":-21.460338,"eighty":-17.211393,"marketCap":1201248026},{"date":"2023-09-22","current":-19.937893,"twenty":-23.078607,"median":-21.067948,"eighty":-17.309925,"marketCap":1306869070},{"date":"2023-09-29","current":-21.876218,"twenty":-23.069233,"median":-21.012104,"eighty":-17.319402,"marketCap":1433920470},{"date":"2023-10-06","current":-37.165618,"twenty":-23.194,"median":-21.285207,"eighty":-17.395476,"marketCap":2436094784},{"date":"2023-10-13","current":-44.162453,"twenty":-23.552536,"median":-21.525005,"eighty":-17.459473,"marketCap":2894716299},{"date":"2023-10-20","current":-45.222784,"twenty":-23.852048,"median":-21.571672,"eighty":-17.466769,"marketCap":2964217822},{"date":"2023-10-27","current":-47.275909,"twenty":-23.892891,"median":-21.592094,"eighty":-17.469621,"marketCap":3098794020},{"date":"2023-11-03","current":-48.538851,"twenty":-24.328544,"median":-21.646551,"eighty":-17.490333,"marketCap":3181576088},{"date":"2023-11-10","current":-38.273225,"twenty":-24.864943,"median":-21.735043,"eighty":-17.514986,"marketCap":2508695101},{"date":"2023-11-17","current":-27.570058,"twenty":-25.04304,"median":-21.781564,"eighty":-17.543453,"marketCap":2122673903},{"date":"2023-11-24","current":-32.691508,"twenty":-27.365869,"median":-21.782692,"eighty":-17.586168,"marketCap":2516984612},{"date":"2023-12-01","current":-35.337541,"twenty":-28.3175,"median":-21.830342,"eighty":-17.593664,"marketCap":2720707940},{"date":"2023-12-08","current":-37.983573,"twenty":-33.138225,"median":-21.904522,"eighty":-17.623452,"marketCap":2924431267},{"date":"2023-12-15","current":-37.177707,"twenty":-34.105722,"median":-22.049686,"eighty":-17.625039,"marketCap":2862386033},{"date":"2023-12-22","current":-20.939825,"twenty":-34.105722,"median":-22.001606,"eighty":-17.644282,"marketCap":1612198995},{"date":"2023-12-29","current":-23.446258,"twenty":-34.065552,"median":-22.068918,"eighty":-17.684898,"marketCap":1805174329},{"date":"2024-01-05","current":-26.187472,"twenty":-34.000259,"median":-22.102574,"eighty":-17.702705,"marketCap":2016225834},{"date":"2024-01-12","current":-28.789086,"twenty":-33.67371,"median":-22.232392,"eighty":-17.746366,"marketCap":2216529345},{"date":"2024-01-19","current":-27.710368,"twenty":-33.290514,"median":-22.259189,"eighty":-17.804907,"marketCap":2133476670},{"date":"2024-01-26","current":-26.745867,"twenty":-33.138225,"median":-22.283013,"eighty":-17.817061,"marketCap":2059217807},{"date":"2024-02-02","current":-28.598724,"twenty":-32.691508,"median":-22.44298,"eighty":-17.823234,"marketCap":2201872991},{"date":"2024-02-09","current":-29.823387,"twenty":-32.667396,"median":-22.576119,"eighty":-17.835432,"marketCap":2296162205},{"date":"2024-02-16","current":-28.427399,"twenty":-32.293017,"median":-22.636267,"eighty":-17.890184,"marketCap":2188682272},{"date":"2024-02-23","current":-26.035182,"twenty":-31.181303,"median":-22.647193,"eighty":-17.91403,"marketCap":2004500750},{"date":"2024-03-01","current":-25.743294,"twenty":-31.092467,"median":-22.775115,"eighty":-17.959972,"marketCap":1982027673},{"date":"2024-03-08","current":-22.849791,"twenty":-30.933832,"median":-22.849791,"eighty":-18.031985,"marketCap":1759251085},{"date":"2024-03-15","current":-18.291889,"twenty":-29.823387,"median":-22.775115,"eighty":-18.031985,"marketCap":1639319082},{"date":"2024-03-22","current":-22.815466,"twenty":-29.601298,"median":-22.761276,"eighty":-18.070517,"marketCap":2044722039},{"date":"2024-03-28","current":-22.311113,"twenty":-29.398245,"median":-22.645883,"eighty":-18.070517,"marketCap":1999521939},{"date":"2024-04-05","current":-20.434088,"twenty":-29.301795,"median":-22.601624,"eighty":-18.089549,"marketCap":1831303011},{"date":"2024-04-12","current":-20.928042,"twenty":-29.107626,"median":-22.568955,"eighty":-18.098906,"marketCap":1875571150},{"date":"2024-04-19","current":-18.81184,"twenty":-29.061939,"median":-22.455039,"eighty":-18.224405,"marketCap":1685917123},{"date":"2024-04-26","current":-20.267704,"twenty":-28.863962,"median":-22.311113,"eighty":-18.256547,"marketCap":1816391638},{"date":"2024-05-03","current":-20.281918,"twenty":-28.794162,"median":-22.289169,"eighty":-18.270537,"marketCap":1817665530},{"date":"2024-05-10","current":-20.105056,"twenty":-28.789086,"median":-22.270856,"eighty":-18.288305,"marketCap":1801815151},{"date":"2024-05-17","current":-17.123915,"twenty":-28.636796,"median":-22.232392,"eighty":-18.098906,"marketCap":1672681180},{"date":"2024-05-24","current":-18.288418,"twenty":-28.476893,"median":-22.116999,"eighty":-18.062811,"marketCap":1786430959},{"date":"2024-05-31","current":-16.11295,"twenty":-28.435013,"median":-22.068918,"eighty":-17.902107,"marketCap":1573929112},{"date":"2024-06-07","current":-26.55105,"twenty":-28.381712,"median":-22.102574,"eighty":-17.902107,"marketCap":2593533072},{"date":"2024-06-14","current":-24.646705,"twenty":-28.337752,"median":-22.198735,"eighty":-17.932407,"marketCap":2407514791},{"date":"2024-06-21","current":-22.312809,"twenty":-28.3175,"median":-22.24579,"eighty":-17.974375,"marketCap":2179537500},{"date":"2024-06-28","current":-18.680713,"twenty":-28.3175,"median":-22.24579,"eighty":-18.00318,"marketCap":1824750754},{"date":"2024-07-05","current":-17.874111,"twenty":-28.267548,"median":-22.198735,"eighty":-17.932407,"marketCap":1745961056},{"date":"2024-07-12","current":-20.408464,"twenty":-28.068249,"median":-22.08815,"eighty":-17.932407,"marketCap":1993519219},{"date":"2024-07-15","current":-20.943017,"twenty":-28.006064,"median":-22.078534,"eighty":-17.941595,"marketCap":2045734877},{"date":"2024-08-02","current":-17.387286,"twenty":-27.943879,"median":-22.068918,"eighty":-17.908069,"marketCap":1698407510},{"date":"2024-08-09","current":-16.461364,"twenty":-27.802578,"median":-21.942986,"eighty":-17.823234,"marketCap":1607962532},{"date":"2024-08-16","current":-20.792004,"twenty":-27.780694,"median":-21.876596,"eighty":-17.821691,"marketCap":2088244945},{"date":"2024-08-23","current":-22.295452,"twenty":-27.74971,"median":-21.929398,"eighty":-17.823234,"marketCap":2239243758},{"date":"2024-08-30","current":-21.822777,"twenty":-27.716713,"median":-21.953525,"eighty":-17.863936,"marketCap":2191770646},{"date":"2024-09-06","current":-21.851252,"twenty":-27.691332,"median":-21.926349,"eighty":-17.874111,"marketCap":2194630472},{"date":"2024-09-13","current":-22.944669,"twenty":-27.671026,"median":-21.901472,"eighty":-17.880178,"marketCap":2304447790},{"date":"2024-09-20","current":-22.067657,"twenty":-27.608415,"median":-21.926349,"eighty":-17.902107,"marketCap":2216365150},{"date":"2024-09-27","current":-23.650834,"twenty":-27.565171,"median":-22.001606,"eighty":-17.941595,"marketCap":2375371475},{"date":"2024-10-04","current":-24.083644,"twenty":-27.536769,"median":-22.068918,"eighty":-18.000093,"marketCap":2418840830},{"date":"2024-10-11","current":-22.130301,"twenty":-27.481934,"median":-22.12365,"eighty":-18.029927,"marketCap":2222656767},{"date":"2024-10-18","current":-22.563112,"twenty":-27.163394,"median":-22.116999,"eighty":-18.055104,"marketCap":2266126122},{"date":"2024-10-25","current":-21.333018,"twenty":-26.967956,"median":-22.11226,"eighty":-18.070517,"marketCap":2142581639},{"date":"2024-10-31","current":-21.560813,"twenty":-26.932422,"median":-22.097835,"eighty":-18.080033,"marketCap":2165460247},{"date":"2024-11-08","current":-21.839862,"twenty":-26.875803,"median":-22.107521,"eighty":-18.096607,"marketCap":2193486542},{"date":"2024-11-15","current":-19.500107,"twenty":-26.820843,"median":-22.068288,"eighty":-18.16223,"marketCap":2155736838},{"date":"2024-11-22","current":-15.573182,"twenty":-26.740791,"median":-22.039183,"eighty":-18.047398,"marketCap":1721615252},{"date":"2024-11-29","current":-17.170432,"twenty":-26.702879,"median":-21.932448,"eighty":-17.923218,"marketCap":1898191276},{"date":"2024-12-06","current":-16.181125,"twenty":-26.575564,"median":-21.883856,"eighty":-17.833409,"marketCap":1788823393},{"date":"2024-12-13","current":-16.424567,"twenty":-26.524021,"median":-21.851252,"eighty":-17.817061,"marketCap":1815735909},{"date":"2024-12-20","current":-15.523314,"twenty":-26.386717,"median":-21.835102,"eighty":-17.715324,"marketCap":1716102339},{"date":"2024-12-27","current":-15.30059,"twenty":-26.269962,"median":-21.822777,"eighty":-17.687076,"marketCap":1691480250},{"date":"2025-01-03","current":-14.601342,"twenty":-26.20397,"median":-21.78933,"eighty":-17.625803,"marketCap":1614178343},{"date":"2025-01-10","current":-14.005686,"twenty":-26.17605,"median":-21.782692,"eighty":-17.604018,"marketCap":1548328570},{"date":"2025-01-17","current":-13.974608,"twenty":-26.160821,"median":-21.780436,"eighty":-17.514986,"marketCap":1544892930},{"date":"2025-01-24","current":-14.482211,"twenty":-26.10752,"median":-21.737354,"eighty":-17.469621,"marketCap":1601008389},{"date":"2025-01-31","current":-15.7046,"twenty":-26.035182,"median":-21.700984,"eighty":-17.381485,"marketCap":1736143575},{"date":"2025-02-07","current":-15.549212,"twenty":-26.032644,"median":-21.680405,"eighty":-17.295679,"marketCap":1718965373},{"date":"2025-02-14","current":-12.622728,"twenty":-25.9819,"median":-21.605123,"eighty":-17.234446,"marketCap":1395442576},{"date":"2025-02-21","current":-12.115125,"twenty":-25.903236,"median":-21.581883,"eighty":-17.21037,"marketCap":1339327118},{"date":"2025-02-28","current":-11.819887,"twenty":-25.84482,"median":-21.567582,"eighty":-17.171628,"marketCap":1306688535},{"date":"2025-03-07","current":-11.01217,"twenty":-25.735679,"median":-21.559435,"eighty":-17.124089,"marketCap":1349277189},{"date":"2025-03-14","current":-9.547313,"twenty":-25.689992,"median":-21.491953,"eighty":-17.045645,"marketCap":1169794078},{"date":"2025-03-21","current":-10.235281,"twenty":-25.609403,"median":-21.417887,"eighty":-16.960589,"marketCap":1254088063},{"date":"2025-03-28","current":-9.33203,"twenty":-25.527539,"median":-21.321628,"eighty":-16.93886,"marketCap":1143416369},{"date":"2025-04-04","current":-7.64253,"twenty":-25.480594,"median":-21.202701,"eighty":-16.831205,"marketCap":936408691},{"date":"2025-04-11","current":-7.043483,"twenty":-25.340669,"median":-21.061141,"eighty":-16.666093,"marketCap":863009847},{"date":"2025-04-17","current":-8.672143,"twenty":-25.329214,"median":-21.042579,"eighty":-16.563339,"marketCap":1062562954},{"date":"2025-04-25","current":-11.068331,"twenty":-25.25285,"median":-20.951128,"eighty":-16.426861,"marketCap":1356158331},{"date":"2025-05-02","current":-12.790591,"twenty":-25.171712,"median":-20.933479,"eighty":-16.305436,"marketCap":1567180008},{"date":"2025-05-09","current":-12.551909,"twenty":-25.070517,"median":-20.891345,"eighty":-16.181125,"marketCap":1537935156},{"date":"2025-05-16","current":-9.774326,"twenty":-25.068859,"median":-20.829252,"eighty":-16.056814,"marketCap":1400885752},{"date":"2025-05-23","current":-9.895696,"twenty":-25.0453,"median":-20.693431,"eighty":-15.839386,"marketCap":1418280862},{"date":"2025-05-30","current":-9.000467,"twenty":-25.01052,"median":-20.672234,"eighty":-15.745511,"marketCap":1289973912},{"date":"2025-06-06","current":-8.619091,"twenty":-25.001825,"median":-20.550917,"eighty":-15.544032,"marketCap":1235314001},{"date":"2025-06-13","current":-8.920177,"twenty":-24.996225,"median":-20.487391,"eighty":-15.387426,"marketCap":1278466562},{"date":"2025-06-20","current":-8.679308,"twenty":-24.952868,"median":-20.449033,"eighty":-14.973238,"marketCap":1243944513},{"date":"2025-06-27","current":-8.462526,"twenty":-24.918331,"median":-20.434088,"eighty":-14.66039,"marketCap":1212874668},{"date":"2025-07-03","current":-8.175491,"twenty":-24.875783,"median":-20.408464,"eighty":-14.607558,"marketCap":1171735893},{"date":"2025-07-11","current":-7.587369,"twenty":-24.818526,"median":-20.385744,"eighty":-14.451133,"marketCap":1087444556},{"date":"2025-07-18","current":-7.840282,"twenty":-24.807686,"median":-20.281918,"eighty":-14.123781,"marketCap":1123692707},{"date":"2025-07-25","current":-7.334457,"twenty":-24.781668,"median":-20.180483,"eighty":-13.987039,"marketCap":1051196404},{"date":"2025-08-01","current":-7.145777,"twenty":-24.722332,"median":-20.085721,"eighty":-13.108576,"marketCap":1024154132},{"date":"2025-08-08","current":-5.211405,"twenty":-24.651853,"median":-19.971704,"eighty":-12.812535,"marketCap":932580977},{"date":"2025-08-15","current":-5.964179,"twenty":-24.61951,"median":-19.937893,"eighty":-12.626872,"marketCap":1067289809},{"date":"2025-08-22","current":-6.234546,"twenty":-24.540145,"median":-19.829477,"eighty":-12.490132,"marketCap":1115672078},{"date":"2025-08-29","current":-6.160517,"twenty":-24.4698,"median":-19.66456,"eighty":-12.119485,"marketCap":1102424552},{"date":"2025-09-05","current":-6.360074,"twenty":-24.389808,"median":-19.576169,"eighty":-11.77845,"marketCap":1138135274},{"date":"2025-09-12","current":-6.720564,"twenty":-24.139365,"median":-19.456275,"eighty":-11.057099,"marketCap":1202644966},{"date":"2025-09-19","current":-7.47695,"twenty":-24.11098,"median":-19.134734,"eighty":-10.896967,"marketCap":1338000122},{"date":"2025-09-26","current":-8.043434,"twenty":-24.072254,"median":-19.014985,"eighty":-10.567565,"marketCap":1439372495},{"date":"2025-10-03","current":-8.568076,"twenty":-24.020356,"median":-18.941828,"eighty":-10.325716,"marketCap":1533257136},{"date":"2025-10-10","current":-9.833009,"twenty":-23.986828,"median":-18.81071,"eighty":-10.186609,"marketCap":1759617036},{"date":"2025-10-17","current":-8.87063,"twenty":-23.947347,"median":-18.74276,"eighty":-9.917033,"marketCap":1587399198},{"date":"2025-10-24","current":-8.548764,"twenty":-23.914099,"median":-18.661907,"eighty":-9.852324,"marketCap":1529801259},{"date":"2025-10-31","current":-10.370526,"twenty":-23.886602,"median":-18.351918,"eighty":-9.836476,"marketCap":1855805594},{"date":"2025-11-07","current":-10.772858,"twenty":-23.868757,"median":-18.327399,"eighty":-9.850579,"marketCap":1927803018},{"date":"2025-11-14","current":-10.08006,"twenty":-23.852048,"median":-18.288418,"eighty":-9.817863,"marketCap":2123717400},{"date":"2025-11-21","current":-9.889979,"twenty":-23.841601,"median":-18.256152,"eighty":-9.836476,"marketCap":2083670157},{"date":"2025-11-28","current":-10.313341,"twenty":-23.799814,"median":-18.097181,"eighty":-9.841018,"marketCap":2172866288},{"date":"2025-12-05","current":-9.460856,"twenty":-23.776121,"median":-18.070517,"eighty":-9.814076,"marketCap":1993260474},{"date":"2025-12-12","current":-19.422835,"twenty":-23.650834,"median":-18.082412,"eighty":-9.833009,"marketCap":4092100041},{"date":"2025-12-16","current":-18.662511,"twenty":-23.640072,"median":-18.097181,"eighty":-9.836213,"marketCap":3931911072}],"updateTime":1766023194158},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GPCR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589356204","title":"Structure details positive trial data for a weight-loss pill, and the stock rockets","url":"https://stock-news.laohu8.com/highlight/detail?id=2589356204","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589356204?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:12","pubTimestamp":1765203120,"startTime":"0","endTime":"0","summary":"The biopharma company now plans to start a Phase 3 trial for the drug next year. Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron.Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly's experimental weight-loss pills.The biopharmaceutical company , which went public in early 2023, is one of only a few independent obesity biotechs with later-stage drugs in development. Investors have been waiting for the Phase 2b readout to understand if aleniglipron has the potential to serve as a \"scaffold\" for Structure's portfolio, according to Stifel analysts.The stock shot up 31.5% in premarket trading, as it heads toward the biggest one-day gain since the record 54.2% rally seen on June 3, 2024. The stock was on track to open around the highest levels seen since June 2024.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Structure details positive trial data for a weight-loss pill, and the stock rockets","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","LU0471298694.HKD","LU0354030511.USD","IE00B4JS1V06.HKD","IE0004445015.USD","IE00B775H168.HKD","LU2471134523.USD","LU2491050154.USD","LU2417539215.USD","LU2236285917.USD","LU0289739699.SGD","LU2552382132.HKD","LU0238689110.USD","LU0820561818.USD","LU0323591593.USD","LU1868837300.USD","LU1868837136.USD","LU1093756325.SGD","BK4599","LU0058720904.USD","LU0266013472.USD","LU2750360997.AUD","LU1983299246.USD","LU0320765992.SGD","SGXZ31699556.SGD","LU1232071149.USD","LU1551013342.USD","LU0882574055.USD","LU1366192091.USD","LU2602419157.SGD","BK4516","LU0385154629.USD","SG9999015986.USD","LU0786609619.USD","IE00BFSS7M15.SGD","LU1712237335.SGD","LU0672654240.SGD","LU0198837287.USD","LU2491050071.SGD","LU0708995401.HKD","LU2471134879.HKD","LU2471134952.CNY","BK4581","LU2023250504.SGD","IE00BJT1NW94.SGD","LU0203202063.USD","LU2456880835.USD","IE00BKPKM429.USD","BK4533","LU1814569148.SGD","LU0256863811.USD","LU2750360641.GBP","LU1093756168.USD","IE00BFSS8Q28.SGD","SG9999018865.SGD","LU0109394709.USD","LU0689472784.USD","LU1291159041.SGD","LU1280957306.USD","LU0234572021.USD","LU0114720955.EUR","LU2237443382.USD","IE00BFTCPJ56.SGD","LU0006306889.USD","LU2237443465.HKD","IE0005OL40V9.USD","LU2237443549.SGD","LU1064131342.USD","IE0004445239.USD","LU1720051108.HKD","IE00B1BXHZ80.USD","IE00BK4W5L77.USD","SG9999014880.SGD","IE00BN29S564.USD","LU1267930730.SGD","LU1057294990.SGD","LU0079474960.USD","IE00BKDWB100.SGD","LU1127390331.HKD","LU1868836914.USD","LU0823416689.USD","LU0823434740.USD","LU0471298777.SGD","SG9999018857.SGD","LU0094547139.USD","LU1868836757.USD","LU0320765059.SGD","LU2265009873.SGD","LU1974910355.USD","BK4588","LU2360106947.USD","LU0061475181.USD","LU2168564065.EUR","GPCR","IE00BJLML261.HKD","LU0820561909.HKD","SGXZ57979304.SGD","LU2168564149.EUR","LU0889565916.HKD","LU2462157665.USD","SG9999015978.USD","SGXZ81514606.USD","LU2461242641.AUD","LU0823434583.USD","LU0432979614.USD","LU2552382058.USD","IE00BK4W5M84.HKD","LU2237443895.HKD","LU2552382215.SGD","LU0203201768.USD","SG9999001176.USD","LU2168563687.JPY","LU0456855351.SGD","IE00B4R5TH58.HKD","LU2237443978.SGD","LU2468319806.SGD","IE00BWXC8680.SGD","BK4007","LU1035775433.USD","LU0417517546.SGD","LU1720051017.SGD","SG9999015945.SGD","LU2106854487.HKD","LU2361044949.HKD","LU1988902786.USD","IE00B2B36J28.USD","LU2108987350.USD","IE00BJJMRZ35.SGD","GB00BDT5M118.USD","LU1917777945.USD","LU1623119135.USD","LU0316494557.USD","LU1804176565.USD","LU0353189763.USD","LU2357305700.SGD","LU2112291526.USD","SGXZ51526630.SGD","LU1023059063.AUD","BK4585","LU1551013425.SGD","LU1061106388.HKD","LU1989771016.USD","BK4534","SG9999001176.SGD","LU2491049909.HKD","LU2746668461.USD","SG9999013999.USD","LU2168564495.EUR","SGXZ99366536.SGD","LU2324357040.USD","IE00B7KXQ091.USD","LU0256863902.USD","LU0122379950.USD","LU2089984988.USD","LU0943347566.SGD","LU1548497426.USD","SG9999014914.USD","LU2264538146.SGD","LU0109391861.USD","LU2361045086.USD","IE00BJJMRY28.SGD","LU2168564222.USD","LU0354030438.USD","LU2211815571.USD","LU2063271972.USD","LU2237438978.USD","LU2087625088.SGD","LU0353189680.USD","LU0882574139.USD","LU2237443622.USD","LU2746668974.SGD","IE00B1XK9C88.USD","LU1323610961.USD","LU0097036916.USD","LU0640476718.USD","LU1069344957.HKD","SG9999014906.USD","SG9999017495.SGD","IE0009355771.USD","LU0106261372.USD","LU2361044865.SGD","SG9999014898.SGD","IE0002141913.USD","LU1868836591.USD","IE00BJJMRX11.SGD","SG9999015952.SGD","LU0466842654.USD","LU2471134796.USD"],"gpt_icon":0},{"id":"2589335319","title":"Structure Therapeutics Shares Reverse Course, Last Down 15% Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2589335319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589335319?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:13","pubTimestamp":1765199597,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE0YN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2589524353","title":"Structure's experimental pill shows 11% weight loss in study, shares up","url":"https://stock-news.laohu8.com/highlight/detail?id=2589524353","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589524353?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:04","pubTimestamp":1765199092,"startTime":"0","endTime":"0","summary":"Structure's experimental pill shows 11% weight loss in study, shares upDec 8  - Structure Therapeutics GPCR.O said on Monday that its obesity pill showed a 11.3% reduction in weight in a mid-stage study.Shares of the biotech jumped 41.8% in premarket trading.  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE0X5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"gpt_icon":0},{"id":"2589353548","title":"Structure Therapeutics Shares Jump 30% Premarket After Data for Its Weight-Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353548?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:04","pubTimestamp":1765199075,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE0X9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GPCR","BK4599"],"gpt_icon":0},{"id":"2589840353","title":"Structure Therapeutics Reports Positive Topline Data From Access Program for Its Once-Daily Oral Small Molecule Glp-1 Receptor Agonist, Aleniglipron","url":"https://stock-news.laohu8.com/highlight/detail?id=2589840353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589840353?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA2FJPGP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GPCR","BK4599","BK4007"],"gpt_icon":0},{"id":"2589353938","title":"Structure Therapeutics Inc - Aleniglipron to Advance to Phase 3 Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353938","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353938?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA2FJPGP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GPCR","BK4599"],"gpt_icon":0},{"id":"2589353933","title":"Structure Therapeutics Inc - Aleniglipron Achieves 11.3% Weight Loss With 120 Mg Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353933?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA2FJPGP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GPCR","BK4599","BK4007"],"gpt_icon":0},{"id":"2589353932","title":"Structure Therapeutics Inc - No Treatment Discontinuations at Lower 2.5 Mg Dose in Access Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353932","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353932?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA2FJPGP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2589337672","title":"BUZZ-Structure Therapeutics down ahead of weight-loss drug data","url":"https://stock-news.laohu8.com/highlight/detail?id=2589337672","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589337672?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:51","pubTimestamp":1765194673,"startTime":"0","endTime":"0","summary":"BUZZ-Structure Therapeutics downahead of weight-loss drug data** Shares of Structure Therapeutics GPCR.O falls 1.4% to $34.1 premarket ** The drug developer on December 8 is set to release data from a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE0NY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","VKTX","BK4139","GPCR","BK4588","BK4599"],"gpt_icon":0},{"id":"2589801875","title":"Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801875","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589801875?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:20","pubTimestamp":1765149600,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Dec.  07, 2025  (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for m","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201156/0/en/Structure-Therapeutics-to-Report-Data-from-ACCESS-Clinical-Program-of-Oral-Small-Molecule-GLP-1-Receptor-Agonist-Aleniglipron-on-December-8-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","LENZ","BK4590","BK4139","GLP","BK4007","BK4144","GPCR","BK4539"],"gpt_icon":0},{"id":"2586724475","title":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up","url":"https://stock-news.laohu8.com/highlight/detail?id=2586724475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586724475?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:39","pubTimestamp":1764077944,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upRewrites paragraph 1, adds Lilly valuation milestone in paragraph 3, updates with Novo trial details in paragraphs 9-0. Promising results of Novo Nordisk's NOVOb.CO experimental obesity drug, amycretin, from a mid-stage trial could give the drugmaker much-needed heft to reclaim lost ground in the weight-loss market, which is projected to reach $150 billion by next decade.Novo said the drug appeared safe and well tolerated, with mostly mild-to-moderate gastrointestinal side effects. Late-stage trials are planned for 2026. Amycretin has a dual-mode action, targeting GLP-1 and amylin hormones.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL4N3X10QM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1069347547.HKD","SG9999014542.SGD","OPK","03165","IE0004445239.USD","LU0079474960.USD","LU2265009873.SGD","MTSR","LU0553294199.USD","LU0265550359.USD","LU0964806797.USD","LU0353189680.USD","IE00BLSP4239.USD","LU0820561909.HKD","LU2063271972.USD","LU2168563687.JPY","LU0109391861.USD","SRRK","LU0094547139.USD","LU1551013342.USD","AMGN","LU0198837287.USD","LU1061106388.HKD","LU2168564065.EUR","BK4592","03692","02105","LU0823416689.USD","GPCR","03933","ALT","VKTX","IE00B4R5TH58.HKD","LU1023059063.AUD","SG9999011175.SGD","LU0738911758.USD","LU1066051225.USD","LU1057294990.SGD","LU0225771236.USD","LU0949170772.SGD","LU0557290698.USD","LU2746668461.USD","SG9999013999.USD","AZN.UK","SG9999015945.SGD","MRK","SG9999015986.USD","LU2168564149.EUR"],"gpt_icon":1},{"id":"2586476870","title":"Jefferies Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586476870","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586476870?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:37","pubTimestamp":1764077828,"startTime":"0","endTime":"0","summary":"Jefferies analyst Roger Song maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $79.00. Accordin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-keeps-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-keeps-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPCR"],"gpt_icon":0},{"id":"2584292607","title":"Structure Therapeutics Inc. Q3 Net Income USD -65.712 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584292607","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584292607?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:58","pubTimestamp":1763571483,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Structure Therapeutics Inc. Q3 operating expenses USD 73.787 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202521:01:51.94 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDwDSNw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4007","GPCR"],"gpt_icon":0},{"id":"1138016060","title":"Stock Track | Structure Therapeutics (GPCR) Soars 5% Pre-Market on Promising Obesity Drug Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1138016060","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138016060?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:00","pubTimestamp":1762786833,"startTime":"0","endTime":"0","summary":"Shares of Structure Therapeutics Inc. (NASDAQ: GPCR) are soaring 5.05% in pre-market trading on Monday, following the company's announcement of positive results from a mid-stage study of its...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GPCR"],"gpt_icon":0},{"id":"2582873987","title":"Press Release: Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873987","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873987?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776000,"startTime":"0","endTime":"0","summary":"SEP-631  Phase 1 Clinical Trial in Healthy Volunteers Ongoing. Robust Financial Position of $561.6 Million Expected to Support Operations at Least into 2029. SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025  -- Septerna, Inc. , a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor  drug discovery, today highlighted key business updates and upcoming milestones and reported financial results for the quarter ended September 30, 2025.\"In the third quarter, we made meaningful progress across our portfolio, highlighted by the selection of SEP-479 as our next-generation PTH1R agonist development candidate for hypoparathyroidism and the initiation of our Phase 1 clinical trial for SEP-631 which targets MRGPRX2 for mast cell-driven diseases,\" said Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna. \"Both programs exemplify the power of our Native Complex Platform to generate differentiated oral small-molecule GPCR therapies with the pote","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4588","BK4097","TM","BK4007","BK4555","BK4599","LU2065732104.USD","PRGS","GPCR","SEPN","BK4585","BK4604","BK4099"],"gpt_icon":0},{"id":"2582145895","title":"The Bull Case For Structure Therapeutics (GPCR) Could Change Following Key Oral Obesity Drug Data Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2582145895","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582145895?lang=en_us&edition=fundamental","pubTime":"2025-11-09 13:25","pubTimestamp":1762665917,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc. recently reported a third quarter 2025 net loss of US$65.71 million, up from US$33.98 million a year earlier, and highlighted advancing milestones in its oral obesity drug pipeline including upcoming clinical data readouts and the expansion of its amylin receptor agonist program.\nThis combination of deepening financial losses and significant pipeline progress has been accompanied by ongoing analyst confidence in the company’s long-term research strategy.\nWe'll...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/the-bull-case-for-structure-therapeutics-gpcr-could-change-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/the-bull-case-for-structure-therapeutics-gpcr-could-change-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GPCR","BK4007","BK4599"],"gpt_icon":0},{"id":"2581882283","title":"Stifel Nicolaus Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581882283","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581882283?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:47","pubTimestamp":1762530478,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $50.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","GPCR"],"gpt_icon":0},{"id":"2581015550","title":"Structure Therapeutics Inc  expected to post a loss of 39 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581015550","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581015550?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:14","pubTimestamp":1762514044,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc  expected to post a loss of39cents a share - Earnings Preview Structure Therapeutics Inc GPCR.OQ GPCR.O is expected to  show no change in quarterly revenue when it reports  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ16Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","BK4599"],"gpt_icon":0},{"id":"2581044019","title":"Structure Therapeutics Inc. unveils strategy to expand access to oral obesity treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2581044019","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581044019?lang=en_us&edition=fundamental","pubTime":"2025-11-07 07:35","pubTimestamp":1762472132,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc. detailed its approach to addressing the growing demand for obesity treatments, highlighting the scalability and accessibility of oral small molecule therapies compared to current injectable GLP-1 options. The company noted that despite over 100 million adults in the U.S. affected by overweight and obesity, current injectable treatments reach less than 5% of the addressable market. Structure Therapeutics projects significant market growth driven by broader access, improved affordability, new oral modalities, and expanding patient awareness. Internal and third-party estimates suggest that by 2030, 25-50% of the U.S. anti-obesity medication market could be served by oral therapies, appealing particularly to needle-hesitant adults and non-specialist prescribers. The company emphasized the convenience and potential cost benefits of oral treatments, as well as the increasing role of telehealth and primary care providers in obesity management. You can access the fu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1qN4KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"gpt_icon":0},{"id":"2581045377","title":"Structure Therapeutics Q3 loss widens to $65.7 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581045377","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581045377?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:41","pubTimestamp":1762465274,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Q3 loss widens to $65.7 mlnOverviewStructure Therapeutics reports Q3 net loss of $65.7 mln, compared to $34 mln in 2024Company maintains strong cash position of $799 mln, fundin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1IX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":66,"code":"91000000","status":"200"}]}}